Tag: Alpha-7 nicotinic acetylcholine receptor partial agonist with alpha-4-beta-2 cross-reactivity derivative of marine alkaloid anabaseine

GTS-21 (also known as DMXBA, DMBX-anabaseine, and 3-(2,4-dimethoxybenzylidene)anabaseine) is a small-molecule partial agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor. The compound is a synthetic derivative of the natural product anabaseine, a marine alkaloid originally isolated from nemertine ribbonworms and from certain ant species, characterized chemically and pharmacologically by William Kem at the University of Florida beginning in the late 1970s. Anabaseine itself is a non-selective nicotinic receptor agonist with substantial muscle-type alpha-1 nicotinic activity that produces neuromuscular toxicity at doses producing central nervous system effects. The 3-(2,4-dimethoxybenzylidene) substitution at the anabaseine scaffold (the structural feature defining DMXBA) substantially increases alpha-7 nicotinic receptor selectivity over the muscle-type receptor and produces the partial agonist functional profile that has supported clinical development. Functional intrinsic activity at human alpha-7 nicotinic receptors expressed in heterologous systems is approximately 30 to 50 percent of the acetylcholine maximum response. Selectivity over the alpha-4-beta-2 nicotinic subtype is incomplete: GTS-21 binds alpha-4-beta-2 with affinity comparable to alpha-7 and acts as a partial agonist at alpha-4-beta-2 in some functional assays and as an antagonist in others, contributing complexity to the in vivo pharmacology that distinguishes GTS-21 from the more selective subsequent candidates encenicline, bradanicline, and PHA-543613. The compound is the longest-studied alpha-7 nicotinic partial agonist in cognitive applications, with continuous research from the early 1990s through the 2020s, and is the principal historical reference compound for the receptor class. GTS-21 was advanced through multiple Phase 1 studies in healthy volunteers in the 1990s and 2000s with positive cognitive signals (the original Kitagawa et al. 2003 healthy volunteer report demonstrated improvements on the Connors Continuous Performance Test), through several Phase 2 studies in schizophrenia cognitive impairment (Olincy et al. 2006 immediate-release proof-of-concept; Olincy et al. 2017 extended-release confirmatory), and through Phase 2 studies in Alzheimer disease and other exploratory cognitive indications. The clinical results have been consistent with a small effect size that produced significant signals in some early studies and not in subsequent larger studies. The compound is metabolized to two principal active metabolites (4-OH-GTS-21 and 2-OH-GTS-21) that retain alpha-7 nicotinic partial agonist activity and contribute to the pharmacodynamic profile; the metabolite contribution complicates the dose-response interpretation and was the principal motivation for the extended-release formulation tested in the Olincy 2017 study. The compound is not in active commercial development as of the most recent monograph revision; research-grade GTS-21 is widely available and continues to be used as a reference alpha-7 partial agonist in fundamental pharmacology. This monograph reviews the chemistry, anabaseine biosynthesis, structural class of GTS-21; the receptor pharmacology including the alpha-4-beta-2 cross-reactivity; the comprehensive human pharmacokinetic record including the active metabolite contribution; the clinical evidence base across schizophrenia, Alzheimer disease, healthy volunteer cognition, and selected inflammatory indications; and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against GTS-21.